Angela Fischer Maranta
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M, Roth P, Bink A, Maranta A, Läubli H, Hottinger A, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobágyi T, Held L, Weller M, Wirsching H. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. BMC cancer 2024; 24:82.
Jan 15, 2024A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Jan 15, 2024BMC cancer 2024; 24:82
Mastall Maximilian, Roth Patrick, Bink Andrea, Maranta Angela Fischer, Läubli Heinz, Hottinger Andreas Felix, Hundsberger Thomas, Migliorini Denis, Ochsenbein Adrian F, Seystahl Katharina, Imbach Lukas L, Hortobágyi Tibor, Held Leonhard, Weller Michael, Wirsching Hans-Georg
Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer
Maranta A, Broder S, Fritzsche C, Knauer M, Thürlimann B, Jochum W, Ruhstaller T. Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. Breast 2020; 51:120-126.
Mar 23, 2020Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer
Mar 23, 2020Breast 2020; 51:120-126
Maranta Angela Fischer, Broder Simon, Fritzsche Constanze, Knauer Michael, Thürlimann Beat, Jochum Wolfram, Ruhstaller Thomas
Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I
Fehr M, Maranta A, Reichegger H, Gillessen Sommer S, Cathomas R. Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I. ESMO Open 2018; 3:e000320.
Mar 8, 2018Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I
Mar 8, 2018ESMO Open 2018; 3:e000320
Fehr Martin, Maranta Angela Fischer, Reichegger Hermann, Gillessen Sommer Silke, Cathomas Richard